within Pharmacolibrary.Drugs.C_CardiovascularSystem.C01D_VasodilatorsUsedInCardiacDiseases.C01DA58_IsosorbideDinitrateCombinations;

model IsosorbideDinitrateCombinations
  extends Pharmacolibrary.Drugs.ATC.C.C01DA58;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>C01DA58</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Isosorbide dinitrate, in combination formulations (ATC code C01DA58), is an organic nitrate vasodilator used for the management and prevention of angina pectoris and chronic heart failure. It acts by releasing nitric oxide, leading to vasodilation of both veins and arteries. Combination products can be used for synergistic effects or to improve clinical profiles. The drug is approved for use in many countries today, usually in chronic heart failure therapy and for angina.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for a typical adult patient, as direct published PK data for the exact combination (C01DA58) is not available. Estimates are extrapolated from data of isosorbide dinitrate monotherapy in healthy adults.</p><h4>References</h4><ol><li><p>Thadani, U, &amp; Whitsett, T (1988). Relationship of pharmacokinetic and pharmacodynamic properties of the organic nitrates. <i>Clinical pharmacokinetics</i> 15(1) 32–43. DOI:<a href=\"https://doi.org/10.2165/00003088-198815010-00003\">10.2165/00003088-198815010-00003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3135973/\">https://pubmed.ncbi.nlm.nih.gov/3135973</a></p></li><li><p>Kinoshita, M, &amp; Sakai, K (1990). Pharmacology and therapeutic effects of nicorandil. <i>Cardiovascular drugs and therapy</i> 4(4) 1075–1088. DOI:<a href=\"https://doi.org/10.1007/BF01856503\">10.1007/BF01856503</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2150592/\">https://pubmed.ncbi.nlm.nih.gov/2150592</a></p></li><li><p>Tam, SW, et al., &amp; Cohn, JN (2007). Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox. <i>Clinical pharmacokinetics</i> 46(10) 885–895. DOI:<a href=\"https://doi.org/10.2165/00003088-200746100-00006\">10.2165/00003088-200746100-00006</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17854237/\">https://pubmed.ncbi.nlm.nih.gov/17854237</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end IsosorbideDinitrateCombinations;
